Sage Therapeutics Inc Total Liabilities
Sage Therapeutics Inc total liabilities. Based on the latest financial reports, Sage Therapeutics Inc (SAGE) has total liabilities worth $54.19 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Sage Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sage Therapeutics Inc (2012–2024)
Total liabilities of Sage Therapeutics Inc from 2012 to 2024. This chart illustrates how Sage Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Sage Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sage Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hankuk Carbon
KO:017960
|
Korea | ₩463.75 Billion |
|
Xian Peri Power Semiconductor Cond
SHE:300831
|
China | CN¥61.50 Million |
|
Huamei Holding
SHE:000607
|
China | CN¥1.79 Billion |
|
Guangdong Xiongsu Technology Group Co Ltd
SHE:300599
|
China | CN¥277.13 Million |
|
Ciwen Media Co Ltd
SHE:002343
|
China | CN¥809.84 Million |
|
Changzhou Almaden Co Ltd
SHE:002623
|
China | CN¥2.88 Billion |
|
Continental Holdings Corp
TW:3703
|
Taiwan | NT$67.54 Billion |
|
Darma Henwa Tbk
JK:DEWA
|
Indonesia | Rp50.36 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Sage Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sage Therapeutics Inc asset portfolio.
Liquidity & Leverage Metrics
Sage Therapeutics Inc Total Liabilities Ratios Explained
Sage Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sage Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sage Therapeutics Inc (2012–2024)
The table below shows the annual total liabilities of Sage Therapeutics Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $82.13 Million | -0.74% |
| 2023-12-31 | $82.75 Million | -20.32% |
| 2022-12-31 | $103.85 Million | +7.89% |
| 2021-12-31 | $96.26 Million | +10.75% |
| 2020-12-31 | $86.91 Million | -37.70% |
| 2019-12-31 | $139.50 Million | +55.45% |
| 2018-12-31 | $89.73 Million | +64.76% |
| 2017-12-31 | $54.46 Million | +51.22% |
| 2016-12-31 | $36.01 Million | +135.06% |
| 2015-12-31 | $15.32 Million | +96.93% |
| 2014-12-31 | $7.78 Million | -80.58% |
| 2013-12-31 | $40.07 Million | +144.48% |
| 2012-12-31 | $16.39 Million | -- |
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more